**Supplementary Table 1. Staging, primary therapy and survival in the overall cohort.**

|  |  |  |
| --- | --- | --- |
| mBCLC staging, *n* (%) | Stage 0 | 16 (10) |
|  | Stage A | 55 (35) |
|  | Stage B | 50 (32) |
|  | Stage C | 24 (15) |
|  | Stage D | 11 (7) |
| Primary therapy, *n* (%) | Surgery | 28 (18) |
|  | RFA | 46 (30) |
|  | TACE | 47 (30) |
|  | SIRT | 8 (5) |
|  | RT | 11 (7) |
|  | ST | 15 (10) |
|  | BSC | 1 (1) |
| Survival, % | 1 year | 69 |
|  | 2 years | 50 |
|  | 5 years | 11 |

BSC, best supportive care; mBCLC, modified Barcelona Clinic Liver Cancer; RFA, radiofrequency ablation; RT, radiotherapy; SIRT, selective internal radiotherapy; ST, systemic therapy; TACE, transarterial chemoembolization.